Amicus Therapeutics announced two new additions to the senior leadership team. Jill Weimer, Ph.D., a developmental neuroscientist and recognized thought leader in the field of neurologic rare disease gene therapy science, has joined as Senior Vice President of Discovery Research and Gene Therapy Science. Dr. Weimer will report to Hung Do, Ph.D., Chief Science Officer and Jeff Castelli, PhD, Chief Portfolio Officer and Head of Gene Therapy as part of Gene Therapy Center of Excellence Leadership Team. 

Simon Jordan, a biotechnology industry executive with a 25-year successful track record of strategy development, rare disease drug launches and international commercial experience for both established and new businesses, was named Senior Vice President of International, reporting to Bradley L. Campbell, President and Chief Operating Officer. 

“On behalf of the Senior Leadership Team, I am pleased to welcome Dr. Jill Weimer and Simon Jordan to Amicus,” stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics. “Jill is a trailblazer within the field of gene therapy science. All of our gene therapy programs for Batten disease originated out of Jill’s research lab, in collaboration with Dr. Brian Kaspar and Dr. Kathrin Meyer at Nationwide Children’s Hospital. Jill will be a valuable leader to advance our Amicus gene therapy science and platforms for rare devastating diseases. Adding additional strength of our senior team is Simon Jordan, who will be instrumental as we continue to grow our international operations. Simon’s leadership responsibilities will include the important expansion of our Galafold^® commercial business and global clinical studies, as well as pre-launch activities for therapies advancing in our pipeline, including the potential for AT-GAA to become the new standard of care in Pompe disease.”